- Companies
- Quanta
Quanta Funding, Investors & Competitors
Quanta has raised $394M across 5 funding rounds, most recently a $60M Series E in November 2024.
Last Quanta funding round
$60M
Series E · Nov 2024
Cumulative funding Quanta raised
$394M
across 5 funding rounds
Key investors in Quanta
b2venture
Novo Holdings
Wellington Partners
Seroba Life Sciences
Glenview Capital Management
Air Liquide
MTIP AG
CITA Investissement
About Quanta
Quanta is a Cambridge, UK-headquartered medical device company focused on haemodialysis systems for home and clinic use. The SC+ cartridge-based system delivers high-efficiency dialysis at flow rates matching in-center machines, supporting transitions from nurse-assisted to home therapy across the patient care continuum via http://www.quantadt.com.
Founded
2008
HQ
Website
Status
Privately held
Customer focus
B2C & B2B
Revenue model
Product sales, Subscription
Quanta Funding History
Quanta has raised a total of $394M across 5 funding rounds.
Quanta's first fundraising round was a $42M Series B in November 2014. The most recent completed round was a $60M Series E in November 2024.
Quanta funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Nov 2024 | Series E | b2venture (lead); Glenview Capital Management (lead); Novo Holdings (lead) | $60M | - |
| Jun 2021 | Series D | Glenview Capital Management (lead); Novo Holdings (lead) | $245M | Quanta Services, Inc. (NYSE: PWR), a publicly traded infrastructure services company focused on electric power, renewable energy, and pipeline projects, reporting annual revenues of $12.98 billion for fiscal year 2021. |
| Jul 2019 | Series C | b2venture (lead); Seroba Life Sciences (lead); Wellington Partners (lead) | $46M | Quanta Dialysis Technologies Ltd is a British medical technology company developing the SC+ personal haemodialysis system for use in clinics and homes to improve dialysis patient outcomes. On July 29, 2019, it announced a first closing of its Series C funding round raising £38 million ($48 million), led by a Swiss private family office with btov Partners (b2venture), and co-led by Wellington Partners and Seroba Life Sciences, with other existing investors participating. The funds were allocated to support the UK commercial launch of the updated SC+ system and a 510(k) submission to the FDA later that year. This Series C round fits into Quanta's funding history, which includes prior Series A and B rounds with the same key investors (b2venture, Seroba Life Sciences, Wellington Partners), followed by later rounds such as a Series D in 2021 and an oversubscribed Series E raising over $60 million led by Novo Holdings, Glenview Capital, and b2venture. Quanta targets the global dialysis market of approximately 3.5 million patients, where innovation in home dialysis is increasingly vital, as highlighted by trends like the American Kidney Health Initiative. The company positions SC+ as a state-of-the-art, patient-friendly solution to enhance value for health systems and patient quality of life. Subsequent developments include FDA clearance and US market expansion via Series E funding. |
| Jan 2018 | Undisclosed stage | MTIP AG | - | MTIP took a minority position in Quanta in 2018 through its first healthcare technology fund. Quanta builds a compact, cartridge-based haemodialysis system designed to run in hospitals, satellite clinics and patients' homes. The investment fell between Quanta's 2014 financing and the Series C round it closed in July 2019, and supported clinical introduction and commercial preparation of the SC+ system. Quanta went on to raise a $245 million round in 2021 and received United States clearance for home haemodialysis in November 2024. |
| Nov 2014 | Series B | Air Liquide (lead); CITA Investissement; b2venture; Kuwait Life Sciences Company; Wellington Partners; NBGI Ventures; Seroba Life Sciences | $42M | - |
Who has invested in Quanta?
10 investors have backed Quanta across its funding rounds, including b2venture, Novo Holdings, Wellington Partners, Seroba Life Sciences, Glenview Capital Management and Air Liquide.
Lead investors include b2venture, Glenview Capital Management, Novo Holdings, Seroba Life Sciences, Wellington Partners and 1 other investor.
Quanta Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Nov 2014 | ||
| 2 | Lead | Jun 2021 | ||
| 2 | Lead | Jun 2021 | ||
| 2 | Lead | Nov 2014 | ||
| 2 | Lead | Nov 2014 | ||
| 1 | Participant | Nov 2014 | ||
| 1 | Participant | Jan 2018 | ||
| 1 | Lead | Nov 2014 | ||
This data is available for Pro users. Sign up to see all 10 Quanta investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialQuanta Competitors
Quanta competitors include listed companies like IDEXX Laboratories, GE HealthCare, United Imaging and Glaukos, and private ones like Dental Monitoring and AcuityMD.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x | ||
| Private | $91M | - | $1B | - | ||
| Private | - | - | $955M | - |
Quanta Public Comps
Quanta is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Abbott, Danaher, Intuitive Surgical, Medtronic and Stryker.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $10B | $3.6B | 13.0x | 11.6x | 36.6x | 25.7x | |||
This data is available for Pro users. Sign up to see all Quanta competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Quanta
| When was Quanta founded? | Quanta was founded in 2008. |
| Where is Quanta headquartered? | Quanta is headquartered in Stratford-upon-Avon, United Kingdom. |
| Is Quanta publicly listed? | No, Quanta is a private, VC-backed company. |
| How much funding has Quanta raised? | Quanta has raised $394M across 5 funding rounds. |
| What was Quanta's last funding round? | Quanta's last funding round was a $60M Series E in November 2024, led by b2venture, Glenview Capital Management and Novo Holdings. |
| Who are Quanta's investors? | Quanta's investors include b2venture, Novo Holdings, Glenview Capital Management, Wellington Partners, Seroba Life Sciences, CITA Investissement, MTIP AG, Air Liquide, Kuwait Life Sciences Company and NBGI Ventures. |
| Which companies are comparable to Quanta? | Companies comparable to Quanta include IDEXX Laboratories, GE HealthCare, United Imaging, Glaukos, Dental Monitoring and AcuityMD. |
See companies similar to Quanta
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




